Scherer Daniel J, Nicholls Stephen J
Cardiovascular Investigation Unit, Royal Adelaide Hospital, University of Adelaide, Adelaide, SA, Australia.
South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia.
Vasc Health Risk Manag. 2015 Mar 25;11:203-9. doi: 10.2147/VHRM.S40134. eCollection 2015.
Despite the clinical benefits of lowering levels of low-density lipoprotein cholesterol, many patients continue to experience cardiovascular events. This residual risk suggests that additional risk factors require aggressive modification to result in more effective prevention of cardiovascular disease. Hypertriglyceridemia has presented a considerable challenge with regard to understanding its role in the promotion of cardiovascular risk. Increasing evidence has established a clear causal role for elevated triglyceride levels in vascular risk. As a result, there is increasing interest in the development of specific therapeutic strategies that directly target hypertriglyceridemia. This has seen a resurgence in the use of omega-3 fatty acids for the therapeutic lowering of triglyceride levels. The role of these agents and other emerging strategies to reduce triglyceride levels in order to decrease vascular risk are reviewed.
尽管降低低密度脂蛋白胆固醇水平具有临床益处，但许多患者仍会发生心血管事件。这种残余风险表明，需要积极改变其他风险因素，以更有效地预防心血管疾病。高甘油三酯血症在理解其在促进心血管风险中的作用方面提出了相当大的挑战。越来越多的证据表明，甘油三酯水平升高在血管风险中具有明确的因果作用。因此，人们对开发直接针对高甘油三酯血症的特定治疗策略越来越感兴趣。这使得ω-3脂肪酸在治疗性降低甘油三酯水平方面的应用再度兴起。本文综述了这些药物以及其他降低甘油三酯水平以降低血管风险的新兴策略的作用。
